Please enable Javascript
SLL
Zanubrutinib Improves PFS Over Doublet Treatment for CLL, SLL
Cecilia Brown
Chronic Lymphocytic Leukemia
|
February 1, 2023
Zanubrutinib led to significant PFS improvements compared with bendamustine plus rituximab in patients with CLL or SLL.
Read More
Gilead Pulls Idelalisib Indications From US Market After Failing to Confirm Clinical Benefit
Sabrina Ahle
Indolent B-Cell Lymphoma
|
November 14, 2022
After failing to complete the requisite confirmatory trials following accelerated approval, Gilead has announced it will ...
Read More
Advertisement
Advertisement
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD
Executive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer